Profile
David Konciak worked as the Head of Worldwide Immuno Oncology at Bristol Myers Squibb Co. He then worked as the VP of Business Development & Strategic Portfolio at Surface Oncology, Inc. from 2018 to 2020.
Konciak received his undergraduate degree from Muhlenberg College and his MBA from The Wharton School of the University of Pennsylvania.
Former positions of David Konciak
| Companies | Position | End |
|---|---|---|
| SURFACE ONCOLOGY, INC. | Corporate Officer/Principal | 2019-12-31 |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | - |
Training of David Konciak
| The Wharton School of the University of Pennsylvania | Masters Business Admin |
| Muhlenberg College | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| Private companies | 1 |
|---|---|
Surface Oncology, Inc.
 Surface Oncology, Inc. BiotechnologyHealth Technology Surface Oncology, Inc. operates as a clinical-stage immuno-oncology company, which engages in the provision of biological pathways critical to the immunosuppressive tumor microenvironment for the development of next-generation cancer therapies. The firm’s pipeline includes wholly-owned lead programs targeting CD39 (SRF617) and IL-27 (SRF388), as well as a preclinical program focused on depleting tumor regulatory T cells via targeting CCR8 (SRF114). Its pipeline also includes licensed product programs, such as a collaboration with Novartis targeting CD73 (NZV930, Phase 1) and a collaboration with GlaxoSmithKline targeting PVRIG (SRF813, preclinical). The company was founded by David S. Grayzel in 2014 and is headquartered in Cambridge, MA. | Health Technology |
- Stock Market
- Insiders
- David Konciak
